e-learning
resources
London 2016
Sunday, 04.09.2016
Inflammatory biomarkers in airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation
Andriana Papaioannou (Vrilissia, Athens, Greece), Andriana Papaioannou, Elissavet Konstantelou, Anastasia Papaporfyriou, Konstantinos Bartziokas, Aris Spathis, Petros Karakitsos, Petros Bakakos, Stelios Loukides, Nikolaos Koulouris, Spyros Papiris, Konstantinos Kostikas
Source:
International Congress 2016 – Inflammatory biomarkers in airway diseases
Session:
Inflammatory biomarkers in airway diseases
Session type:
Oral Presentation
Number:
489
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Andriana Papaioannou (Vrilissia, Athens, Greece), Andriana Papaioannou, Elissavet Konstantelou, Anastasia Papaporfyriou, Konstantinos Bartziokas, Aris Spathis, Petros Karakitsos, Petros Bakakos, Stelios Loukides, Nikolaos Koulouris, Spyros Papiris, Konstantinos Kostikas. Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation. Eur Respir J 2016; 48: Suppl. 60, 489
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Risk factors associated with the development of interstitial lung abnormalities
Related content which might interest you:
Serum periostin in patients hospitalized for COPD exacerbations
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015
Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation
Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench
Year: 2013
Characterization of readmissions in patients hospitalized with COPD exacerbation
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Eosinophilia as marker of outcome in hospitalised patients with AECOPD
Source: Annual Congress 2013 –COPD and infections
Year: 2013
COPD patients admitted in ICU for acute exacerbation: Impact of exacerbation factors on prognosis
Source: International Congress 2016 – Dealing with the complexity of critically-ill patients
Year: 2016
BNP level in patients with COPD exacerbations
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Gender differences in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Rehospitalizations for an acute exacerbation among patients with COPD
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
IL-17A is specifically elevated in NTHi-associated AECOPD and end-stage COPD
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Risk factors for another hospitalization in COPD patients hospitalized for exacerbation
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
Neutrophil CD 64 expression as a diagnostic marker of pneumonia in patients with acute COPD exacerbation
Source: International Congress 2014 – Markers
Year: 2014
Increased circulating alveolar epithelial microparticles in COPD patients
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Survival in COPD patients with hospitalization due to exacerbation
Source: International Congress 2014 – Longitudinal studies of respiratory disease
Year: 2014
Vitamin D, exacerbations and hospitalizations in COPD patients
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Recording and response to hyperglycaemia in patients presenting with infective exacerbations of COPD
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013
Relationship between CRP levels and the severity of COPD acute exacerbations among group D COPD patients.
Source: Virtual Congress 2020 – COPD phenotypes
Year: 2020
Clinical profile and treatment of elderly patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. A comparative syudy
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Comparative study of hospitalized patients with acute exacerbation of COPD with and without carbon dioxide retention
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
The role of biomarkers in predicting outcomes in acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept